Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 483 entries
Sorted by: Best Match Show Resources per page
Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method.

The Eurasian journal of medicine

Aktas AE, Yigit N, Aktas A, Gozubuyuk SG.
PMID: 25610290
Eurasian J Med. 2014 Feb;46(1):26-31. doi: 10.5152/eajm.2014.05.

OBJECTIVE: Dermatomycosis is an infection with fungi related to the skin: glabrous skin, hair and/or nails. Oral treatment of fungal infections in dermatology has become a preferred modality for the management of these very common conditions. Although there are...

Cite
Aktas AE, Yigit N, Aktas A, et al. Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method. Eurasian J Med. 2014;46(1):26-31doi: 10.5152/eajm.2014.05.
Aktas, A. E., Yigit, N., Aktas, A., & Gozubuyuk, S. G. (2014). Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method. The Eurasian journal of medicine, 46(1), 26-31. https://doi.org/10.5152/eajm.2014.05
Aktas, Ayse Esin, et al. "Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method." The Eurasian journal of medicine vol. 46,1 (2014): 26-31. doi: https://doi.org/10.5152/eajm.2014.05
Aktas AE, Yigit N, Aktas A, Gozubuyuk SG. Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method. Eurasian J Med. 2014 Feb;46(1):26-31. doi: 10.5152/eajm.2014.05. PMID: 25610290; PMCID: PMC4261438.
Copy Download .nbib Format: NLM
Pathogen distribution and drug resistance in a burn ward: a three-year retrospective analysis of a single center in China.

International journal of clinical and experimental medicine

Cen H, Wu Z, Wang F, Han C.
PMID: 26770555
Int J Clin Exp Med. 2015 Oct 15;8(10):19188-99. eCollection 2015.

To investigate the spread of multiple-resistant strain in a burn ward to inform clinical administration of antibiotic drugs, burn wound treatment and decision-making for infection control. A 3-year retrospective analysis was conducted. Specimens from wounds, blood, catheter, sputum, urine...

Cite
Cen H, Wu Z, Wang F, et al. Pathogen distribution and drug resistance in a burn ward: a three-year retrospective analysis of a single center in China. Int J Clin Exp Med. 2015;8(10):19188-99
Cen, H., Wu, Z., Wang, F., & Han, C. (2015). Pathogen distribution and drug resistance in a burn ward: a three-year retrospective analysis of a single center in China. International journal of clinical and experimental medicine, 8(10), 19188-99.
Cen, Hanghui, et al. "Pathogen distribution and drug resistance in a burn ward: a three-year retrospective analysis of a single center in China." International journal of clinical and experimental medicine vol. 8,10 (2015): 19188-99.
Cen H, Wu Z, Wang F, Han C. Pathogen distribution and drug resistance in a burn ward: a three-year retrospective analysis of a single center in China. Int J Clin Exp Med. 2015 Oct 15;8(10):19188-99. eCollection 2015. PMID: 26770555; PMCID: PMC4694455.
Copy Download .nbib Format: NLM
Detection of dermatophytes in healthy companion dogs and cats in eastern India.

Iranian journal of veterinary research

Debnath C, Mitra T, Kumar A, Samanta I.
PMID: 27656224
Iran J Vet Res. 2016;17(1):20-4.

In recent times increasing occurrence of dermatophytosis, especially among the school children in eastern India was evidenced along with increased tendency of keeping companion animals such as dogs and cats. This study was undertaken to detect the occurrence of...

Cite
Debnath C, Mitra T, Kumar A, et al. Detection of dermatophytes in healthy companion dogs and cats in eastern India. Iran J Vet Res. 2016;17(1):20-4
Debnath, C., Mitra, T., Kumar, A., & Samanta, I. (2016). Detection of dermatophytes in healthy companion dogs and cats in eastern India. Iranian journal of veterinary research, 17(1), 20-4.
Debnath, C, et al. "Detection of dermatophytes in healthy companion dogs and cats in eastern India." Iranian journal of veterinary research vol. 17,1 (2016): 20-4.
Debnath C, Mitra T, Kumar A, Samanta I. Detection of dermatophytes in healthy companion dogs and cats in eastern India. Iran J Vet Res. 2016;17(1):20-4. PMID: 27656224; PMCID: PMC4898015.
Copy Download .nbib Format: NLM
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.

Pharmacology research & perspectives

Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG.
PMID: 26516590
Pharmacol Res Perspect. 2015 Oct;3(5):e00179. doi: 10.1002/prp2.179. Epub 2015 Oct 12.

Evacetrapib is an investigational cholesteryl ester transfer protein inhibitor (CETPi) for reduction of risk of major adverse cardiovascular events in patients with high-risk vascular disease. Understanding evacetrapib disposition, metabolism, and the potential for drug-drug interactions (DDI) may help guide...

Cite
Cannady EA, Wang MD, Friedrich S, et al. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacol Res Perspect. 2015;3(5):e00179doi: 10.1002/prp2.179.
Cannady, E. A., Wang, M. D., Friedrich, S., Rehmel, J. L., Yi, P., Small, D. S., Zhang, W., & Suico, J. G. (2015). Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacology research & perspectives, 3(5), e00179. https://doi.org/10.1002/prp2.179
Cannady, Ellen A, et al. "Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors." Pharmacology research & perspectives vol. 3,5 (2015): e00179. doi: https://doi.org/10.1002/prp2.179
Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacol Res Perspect. 2015 Oct;3(5):e00179. doi: 10.1002/prp2.179. Epub 2015 Oct 12. PMID: 26516590; PMCID: PMC4618649.
Copy Download .nbib Format: NLM
Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome.

Indian journal of nephrology

Iyengar A, Kamath N, Phadke KD, Bitzan M.
PMID: 24339519
Indian J Nephrol. 2013 Nov;23(6):419-23. doi: 10.4103/0971-4065.120338.

Cyclosporine A (CyA) is an effective agent for the treatment of glucocorticoid-dependent idiopathic nephrotic syndrome (GCDNS), but costs are prohibitive in resource-poor societies. The objectives of this study were to evaluate the efficacy and safety of reducing the dose...

Cite
Iyengar A, Kamath N, Phadke KD, et al. Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome. Indian J Nephrol. 2013;23(6):419-23doi: 10.4103/0971-4065.120338.
Iyengar, A., Kamath, N., Phadke, K. D., & Bitzan, M. (2013). Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome. Indian journal of nephrology, 23(6), 419-23. https://doi.org/10.4103/0971-4065.120338
Iyengar, A, et al. "Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome." Indian journal of nephrology vol. 23,6 (2013): 419-23. doi: https://doi.org/10.4103/0971-4065.120338
Iyengar A, Kamath N, Phadke KD, Bitzan M. Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome. Indian J Nephrol. 2013 Nov;23(6):419-23. doi: 10.4103/0971-4065.120338. PMID: 24339519; PMCID: PMC3841509.
Copy Download .nbib Format: NLM
Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients.

World journal of nephrology

Khan E, Killackey M, Kumbala D, LaGuardia H, Liu YJ, Qin HZ, Alper B, Paramesh A, Buell J, Zhang R.
PMID: 25332902
World J Nephrol. 2014 Aug 06;3(3):107-13. doi: 10.5527/wjn.v3.i3.107.

AIM: To study the long-term outcome of ketoconazole and tacrolimus combination in kidney transplant recipients.METHODS: From 2006 to 2010, ketoconazole was given in 199 patients and was continued for at least 1 year or until graft failure (Group 1),...

Cite
Khan E, Killackey M, Kumbala D, et al. Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. World J Nephrol. 2014;3(3):107-13doi: 10.5527/wjn.v3.i3.107.
Khan, E., Killackey, M., Kumbala, D., LaGuardia, H., Liu, Y. J., Qin, H. Z., Alper, B., Paramesh, A., Buell, J., & Zhang, R. (2014). Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. World journal of nephrology, 3(3), 107-13. https://doi.org/10.5527/wjn.v3.i3.107
Khan, Enver, et al. "Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients." World journal of nephrology vol. 3,3 (2014): 107-13. doi: https://doi.org/10.5527/wjn.v3.i3.107
Khan E, Killackey M, Kumbala D, LaGuardia H, Liu YJ, Qin HZ, Alper B, Paramesh A, Buell J, Zhang R. Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. World J Nephrol. 2014 Aug 06;3(3):107-13. doi: 10.5527/wjn.v3.i3.107. PMID: 25332902; PMCID: PMC4202487.
Copy Download .nbib Format: NLM
Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model.

CPT: pharmacometrics & systems pharmacology

Leil TA, Kasichayanula S, Boulton DW, LaCreta F.
PMID: 24964282
CPT Pharmacometrics Syst Pharmacol. 2014 Jun 25;3:e120. doi: 10.1038/psp.2014.18.

A Bayesian mechanism-based pharmacokinetic/pharmacodynamic model of cytochrome P450 3A4 (CYP3A4) activity was developed based on a clinical study of the effects of ketoconazole and rifampin on midazolam exposure and plasma 4β-hydroxycholesterol (4βHC) concentrations. Simulations from the model demonstrated that...

Cite
Leil TA, Kasichayanula S, Boulton DW, et al. Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model. CPT Pharmacometrics Syst Pharmacol. 2014;3:e120doi: 10.1038/psp.2014.18.
Leil, T. A., Kasichayanula, S., Boulton, D. W., & LaCreta, F. (2014). Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model. CPT: pharmacometrics & systems pharmacology, 3e120. https://doi.org/10.1038/psp.2014.18
Leil, T A, et al. "Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model." CPT: pharmacometrics & systems pharmacology vol. 3 (2014): e120. doi: https://doi.org/10.1038/psp.2014.18
Leil TA, Kasichayanula S, Boulton DW, LaCreta F. Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 25;3:e120. doi: 10.1038/psp.2014.18. PMID: 24964282; PMCID: PMC4076805.
Copy Download .nbib Format: NLM
Cushing's Disease Presented by Reversible Dilated Cardiomyopathy.

Case reports in cardiology

Aydoğan Bİ, Gerede DM, Canpolat AG, Erdoğan MF.
PMID: 26649206
Case Rep Cardiol. 2015;2015:980897. doi: 10.1155/2015/980897. Epub 2015 Nov 16.

Introduction. Dilated cardiomyopathy is rarely reported among CS patients especially without hypertension and left ventricular hypertrophy. Materials and Methods. We hereby report a Cushing's syndrome case presenting with dilated cardiomyopathy. Results. A 48-year-old female patient was admitted to our...

Cite
Aydoğan Bİ, Gerede DM, Canpolat AG, et al. Cushing's Disease Presented by Reversible Dilated Cardiomyopathy. Case Rep Cardiol. 2015;2015:980897doi: 10.1155/2015/980897.
Aydoğan, B. �. �., Gerede, D. M., Canpolat, A. G., & Erdoğan, M. F. (2015). Cushing's Disease Presented by Reversible Dilated Cardiomyopathy. Case reports in cardiology, 2015980897. https://doi.org/10.1155/2015/980897
Aydoğan, Berna İmge, et al. "Cushing's Disease Presented by Reversible Dilated Cardiomyopathy." Case reports in cardiology vol. 2015 (2015): 980897. doi: https://doi.org/10.1155/2015/980897
Aydoğan Bİ, Gerede DM, Canpolat AG, Erdoğan MF. Cushing's Disease Presented by Reversible Dilated Cardiomyopathy. Case Rep Cardiol. 2015;2015:980897. doi: 10.1155/2015/980897. Epub 2015 Nov 16. PMID: 26649206; PMCID: PMC4663299.
Copy Download .nbib Format: NLM
Pre-mRNA splicing is modulated by antifungal drugs in the filamentous fungus Neurospora crassa.

FEBS open bio

Mendes NS, Silva PM, Silva-Rocha R, Martinez-Rossi NM, Rossi A.
PMID: 27239448
FEBS Open Bio. 2016 Mar 14;6(4):358-68. doi: 10.1002/2211-5463.12047. eCollection 2016 Apr.

For this study, we sought to identify pre-mRNA processing events modulated by changes in extracellular pH, inorganic phosphate, and antifungal drugs. We examined genes with at least four putative introns whose transcriptional level responded to these effectors. We showed...

Cite
Mendes NS, Silva PM, Silva-Rocha R, et al. Pre-mRNA splicing is modulated by antifungal drugs in the filamentous fungus Neurospora crassa. FEBS Open Bio. 2016;6(4):358-68doi: 10.1002/2211-5463.12047.
Mendes, N. S., Silva, P. M., Silva-Rocha, R., Martinez-Rossi, N. M., & Rossi, A. (2016). Pre-mRNA splicing is modulated by antifungal drugs in the filamentous fungus Neurospora crassa. FEBS open bio, 6(4), 358-68. https://doi.org/10.1002/2211-5463.12047
Mendes, Niege S, et al. "Pre-mRNA splicing is modulated by antifungal drugs in the filamentous fungus Neurospora crassa." FEBS open bio vol. 6,4 (2016): 358-68. doi: https://doi.org/10.1002/2211-5463.12047
Mendes NS, Silva PM, Silva-Rocha R, Martinez-Rossi NM, Rossi A. Pre-mRNA splicing is modulated by antifungal drugs in the filamentous fungus Neurospora crassa. FEBS Open Bio. 2016 Mar 14;6(4):358-68. doi: 10.1002/2211-5463.12047. eCollection 2016 Apr. PMID: 27239448; PMCID: PMC4821360.
Copy Download .nbib Format: NLM
In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes.

Asian Pacific journal of tropical medicine

Sumsakul W, Chaijaroenkul W, Na-Bangchang K.
PMID: 26614990
Asian Pac J Trop Med. 2015 Nov;8(11):914-918. doi: 10.1016/j.apjtm.2015.10.016. Epub 2015 Oct 09.

OBJECTIVE: To investigate the propensity of plumbagin to inhibit the three isoforms of human cytochrome P450 (CYP), i.e., CYP1A2, CYP2C19, and CYP3A4 using human liver microsomes in vitro.METHODS: Inhibitory effects of plumbagin on the three human CYP isoforms were...

Cite
Sumsakul W, Chaijaroenkul W, Na-Bangchang K. In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes. Asian Pac J Trop Med. 2015;8(11):914-918doi: 10.1016/j.apjtm.2015.10.016.
Sumsakul, W., Chaijaroenkul, W., & Na-Bangchang, K. (2015). In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes. Asian Pacific journal of tropical medicine, 8(11), 914-918. https://doi.org/10.1016/j.apjtm.2015.10.016
Sumsakul, Wiriyaporn, et al. "In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes." Asian Pacific journal of tropical medicine vol. 8,11 (2015): 914-918. doi: https://doi.org/10.1016/j.apjtm.2015.10.016
Sumsakul W, Chaijaroenkul W, Na-Bangchang K. In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes. Asian Pac J Trop Med. 2015 Nov;8(11):914-918. doi: 10.1016/j.apjtm.2015.10.016. Epub 2015 Oct 09. PMID: 26614990.
Copy Download .nbib Format: NLM
Vitamin D3 May Ameliorate the Ketoconazole Induced Adrenal Injury: Histological and Immunohistochemical Studies on Albino Rats.

Acta histochemica et cytochemica

Khalil MS.
PMID: 26379312
Acta Histochem Cytochem. 2015 Aug 27;48(4):103-13. doi: 10.1267/ahc.14062. Epub 2015 Aug 20.

Ketoconazole (KZ) is used widely for treating the superficial, systemic fungal activities and hyperandrogenemic states. Its uses are limited by its deleterious effect on histological structure and function of the adrenal cortex. This study investigates whether vitamin D3 supplement...

Cite
Khalil MS. Vitamin D3 May Ameliorate the Ketoconazole Induced Adrenal Injury: Histological and Immunohistochemical Studies on Albino Rats. Acta Histochem Cytochem. 2015;48(4):103-13doi: 10.1267/ahc.14062.
Khalil, M. S. (2015). Vitamin D3 May Ameliorate the Ketoconazole Induced Adrenal Injury: Histological and Immunohistochemical Studies on Albino Rats. Acta histochemica et cytochemica, 48(4), 103-13. https://doi.org/10.1267/ahc.14062
Khalil, Mahmoud Salah. "Vitamin D3 May Ameliorate the Ketoconazole Induced Adrenal Injury: Histological and Immunohistochemical Studies on Albino Rats." Acta histochemica et cytochemica vol. 48,4 (2015): 103-13. doi: https://doi.org/10.1267/ahc.14062
Khalil MS. Vitamin D3 May Ameliorate the Ketoconazole Induced Adrenal Injury: Histological and Immunohistochemical Studies on Albino Rats. Acta Histochem Cytochem. 2015 Aug 27;48(4):103-13. doi: 10.1267/ahc.14062. Epub 2015 Aug 20. PMID: 26379312; PMCID: PMC4564376.
Copy Download .nbib Format: NLM
Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis.

Endocrinology, diabetes & metabolism case reports

Schwetz V, Aberer F, Stiegler C, R Pieber T, Obermayer-Pietsch B, Pilz S.
PMID: 26380091
Endocrinol Diabetes Metab Case Rep. 2015;2015:150027. doi: 10.1530/EDM-15-0027. Epub 2015 May 21.

UNLABELLED: Cushing's syndrome (CS) due to ectopic ACTH production accounts for about 10% of all types of CS and is frequently associated with metabolic alkalosis. Treatment of CS involves surgical resection and/or medical therapy to control hypercortisolism. We present...

Cite
Schwetz V, Aberer F, Stiegler C, et al. Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis. Endocrinol Diabetes Metab Case Rep. 2015;2015:150027doi: 10.1530/EDM-15-0027.
Schwetz, V., Aberer, F., Stiegler, C., R Pieber, T., Obermayer-Pietsch, B., & Pilz, S. (2015). Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis. Endocrinology, diabetes & metabolism case reports, 2015150027. https://doi.org/10.1530/EDM-15-0027
Schwetz, Verena, et al. "Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis." Endocrinology, diabetes & metabolism case reports vol. 2015 (2015): 150027. doi: https://doi.org/10.1530/EDM-15-0027
Schwetz V, Aberer F, Stiegler C, R Pieber T, Obermayer-Pietsch B, Pilz S. Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis. Endocrinol Diabetes Metab Case Rep. 2015;2015:150027. doi: 10.1530/EDM-15-0027. Epub 2015 May 21. PMID: 26380091; PMCID: PMC4570129.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 483 entries